Evaluating Demographic Representation in Clinical Trials: Use of the Adaptive Coronavirus Disease 2019 Treatment Trial (ACTT) as a Test Case

Ana M. Ortega-Villa*, Noreen A. Hynes, Corri B. Levine, Katherine Yang, Zanthia Wiley, Nikolaus Jilg, Jing Wang, Jennifer A. Whitaker, Christopher J. Colombo, Seema U. Nayak, Hannah Jang Kim, Nicole M. Iovine, Dilek Ince, Stuart H. Cohen, Adam J. Langer, Jonathan M. Wortham, Robert L. Atmar, Hana M. El Sahly, Mamta K. Jain, Aneesh K. MehtaCameron R. Wolfe, Carlos A. Gomez, Tatiana Beresnev, Richard A. Mularski, Catharine I. Paules, Andre C. Kalil, Angela R. Branche, Annie Luetkemeyer, Barry S. Zingman, Jocelyn Voell, Michael Whitaker, Michelle S. Harkins, Richard T. DaveyJr, Robert Grossberg, Sarah L. George, Victor Tapson, William R. Short, Varduhi Ghazaryan, Constance A. Benson, Lori E. Dodd, Daniel A. Sweeney, Kay M. Tomashek

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Evaluating Demographic Representation in Clinical Trials: Use of the Adaptive Coronavirus Disease 2019 Treatment Trial (ACTT) as a Test Case'. Together they form a unique fingerprint.

Medicine & Life Sciences